+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
MALE
ID06150417

Radiation Therapy Targeting Metastatic Sites Compared to Standard Prostate Treatment with Long-term Hormone Therapy for Men with Newly Diagnosed Oligometastatic Prostate Cancer

Led by Case Comprehensive Cancer Center · Updated on 2026-09-15

200

Participants Needed

3

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating if adding radiation therapy targeted to metastatic sites metastasis-directed radiotherapy or MDRT at diagnosis improves control of metastatic prostate cancer compared to the usual treatment. This is a phase 2 trial focused on men with newly diagnosed metastatic prostate cancer receiving long-term hormone therapy. The study aims to compare standard care alone versus standard care plus MDRT to assess disease control benefits. Participants receive standard systemic therapy with androgen deprivation therapy ADT and androgen receptor signaling inhibitors ARSI for 12 months. Local therapy includes radiotherapy RT to the prostate or surgery to remove the prostate radical prostatectomy. Those randomized to the MDRT arm will also receive targeted radiotherapy to metastatic lesions by Week 24. Local therapy should be completed by Week 20. During the 12-month study period, participants undergo treatment and regular evaluations including imaging to assess disease progression. Researchers measure failure-free survival up to 5 years after treatment to evaluate effectiveness. Additional outcomes include overall survival, progression-free survival, quality of life assessments, and skeletal-related events. Participants will be followed by their doctors for up to five years according to standard care after study completion.

CONDITIONS

Brief Title

MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)

Research Team

A

Angela Y Jia, MD, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here